Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p58 | (1) | ICCBH2019

The validity of serum alkaline phosphatase to identify nutritional rickets in Nigerian children on a calcium-deprived diet

Thacher Tom , Sempos Christopher , Durazo-Arvizu Ramon , Munns Craig , Fischer Philip , Pettifor John

Objectives: Nutritional rickets results from the interaction of poor vitamin D status and limited calcium intake. Elevated serum alkaline phosphatase is a marker of impaired mineralization in many forms of rickets. We assessed the reliability of serum alkaline phosphatase in identifying nutritional rickets in calcium-deprived Nigerian children.Methods: We reanalyzed data from a case-control study of Nigerian children with active rickets (cases) and age-,...

ba0007p170 | (1) | ICCBH2019

Serum 25-hydroxyvitamin D requirements to prevent rickets in Nigerian children on a calcium-deprived diet

Thacher Tom , Sempos Christopher , Durazo-Arvizu Ramon , Munns Craig , Fischer Philip , Pettifor John

Objectives: Nutritional rickets results from the interaction of poor vitamin D status and limited calcium intake. Vitamin D requirements are greater in children with limited intake of calcium. We sought to determine the serum 25-hydroxyvitamin D [25(OH)D] concentration that can prevent rickets in calcium-deprived Nigerian children.Methods: We reanalyzed data from a case-control study of Nigerian children with active rickets (cases) and age-, sex-, and we...

ba0004is18 | (1) (1) | ICCBH2015

Management of sclerosing bone disease

Whyte Michael P

Many disorders cause osteosclerosis, and many exclusively affect adults. Pediatricians are likely to encounter those that are Mendelian diseases, with most still classified as ‘dysplasias’ although now understood at the gene level. Thus, there is promise for defining their molecular and biochemical pathogeneses, and for developing targeted medical treatments. Sclerosing bone dysplasias too have become the ‘turf’ of the metabolic bone disease specialist. How...

ba0004is18biog | (1) (1) | ICCBH2015

Management of sclerosing bone disease

Whyte Michael P

Biographical DetailsMichael P Whyte is Professor of Medicine, Pediatrics, and Genetics at the Washington University School of Medicine, a staff member of Barnes-Jewish Hospital and St. Louis Children’s Hospital, and Medical-Scientific Director at the Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children in St. Louis, Missouri, USA.<p class="abst...

ba0004oc8 | (1) | ICCBH2015

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Munns Craig , Peacock Lauren , Mikulec Kathy , Kneissel Michaela , Kramer Ina , Cheng Tegan , Schindeler Aaron , Little David

Introduction: Bisphosphonate treatment in children with osteogenesis imperfecta reduces bone catabolism and relies on modelling to form new bone. An anabolic treatment, anti-sclerostin antibody (Anti-SOST Ab), is being investigated in clinical trials. We hypothesized that combined treatment may produce superior outcomes in OI.Methods: Female Col1a2 G610C mice and their wild type littermates (WT) were treated from week 5 to week 9 of life with either sali...

ba0002p163 | (1) | ICCBH2013

Phenotype–genotype correlation and role of ancillary investigations in atypical and rare forms of osteogenesis imperfecta

Balasubramanian Meena , Parker Michael , Bishop Nicholas J

Background: Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. It is a variable condition with a range of clinical severity. About 90% of patients with a clinical diagnosis of OI have a mutation in the COL1A1 or COL1A2 genes, which shows an autosomal dominant pattern (AD) of inheritance. Other genes are associated with the autosomal recessive (AR) ...

ba0004is13 | (1) (1) | ICCBH2015

Shared therapeutic targets in genetic skeletal diseases

Briggs Michael D , Pirog Katarzyna A , Bell Peter A

Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that primarily affect the development and homeostasis of the osseous skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic diseases, GSDs have an overall prevalence of at least 1/4000 child. Qualitative defects in cartilage struc...

ba0004is13biog | (1) (1) | ICCBH2015

Shared therapeutic targets in genetic skeletal diseases

Briggs Michael D , Pirog Katarzyna A , Bell Peter A

Biographical DetailsMichael D Briggs obtained his PhD at the MRC Clinical Research Centre, Harrow, studying the genetic basis of osteogenesis imperfecta. He undertook postdoctoral work at UCLA identifying the genetic basis of chondrodysplasias. In 1996 Mike moved to Manchester as an AR-UK Fellow to continue studying disease mechanisms in chondrodysplasia. In 2004 he was awarded a Wellcome...

ba0004p22 | (1) | ICCBH2015

Racing to better bone health! A 6-month calcium and vitamin D randomised controlled trial in young male jockeys

Silk Leslie , Greene David , Baker Michael

Objectives: Young male jockeys undertake calorie restriction and high volumes of physical activity during periods of musculoskeletal growth and development. Previous research shows that jockeys have compromised bone health1–4 and display disordered eating5–7. Restricted intakes of calcium and vitamin D, together with excessive amounts of exercise, increase the risk of osteoporosis in males8. The aim of this study was to establish whet...

ba0004p196 | (1) | ICCBH2015

Early onset cataract in an infant with activating calcium sensing receptor mutation

Ramaswamy Priya , Ryalls Michael , Allgrove Jeremy

Background: A 3 month-old boy was born at term, to non-consanguineous parents by spontaneous vaginal delivery, in good condition, weighing 4.19 kg. Newborn examination, including eyes, was normal prior to discharge. He has two older brothers in good health.Presenting problem: He was admitted at 7 days of life with focal seizures and hypocalcaemia (1.5 mmol/l), hypomagnesaemia (0.6 mmol/l), hyperphosphataemia (3.7 mmol/l) and inappropriately low parathyro...